PAPP-A Rapid Test Device (Serum)

PAPP-A serum refers to the level of Pregnancy-Associated Plasma Protein A measured in a serum blood sample. During pregnancy, PAPP-A is produced by the placenta and is one of the markers measured during first-trimester combined screening. This screening is generally performed during early pregnancy, commonly between 11 and 14 weeks, and helps doctors evaluate pregnancy-related risk factors.

The PAPP-A Rapid Test Device (Serum) is intended for the professional in vitro diagnostic detection of Pregnancy-Associated Plasma Protein A in human serum. It supports first-trimester prenatal screening workflows and pregnancy-related risk assessment when used with other clinical findings.

Applications

• First-trimester prenatal screening workflows
• Maternal serum biomarker testing
• Pregnancy-Associated Plasma Protein A level assessment
• Risk evaluation for selected chromosomal abnormalities
• Pregnancy monitoring support where low PAPP-A is clinically relevant
• Laboratory-based testing in maternity and gynecology care
• Supporting combined screening with other markers and ultrasound findings

• PAPP-A testing is not a standalone diagnostic test. It is generally used as part of a wider prenatal screening approach with other biochemical markers, ultrasound findings, maternal age, gestational age, and clinical history.
• Low PAPP-A levels may be associated with increased risk of selected chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome when evaluated with other screening markers.
• Low PAPP-A may also be linked with placental insufficiency, fetal growth restriction, preterm delivery, pre-eclampsia, and low birth weight. However, low PAPP-A does not confirm that a pregnancy complication will occur. Results must always be reviewed by qualified healthcare professionals.

PAPP-A is important because it reflects placental activity during early pregnancy. The placenta supports fetal growth by providing oxygen and nutrients. From a clinical point of view, the PAPP-A Rapid Test Device (Serum) helps laboratories deliver useful biomarker information to healthcare providers. It can assist in early pregnancy care planning, especially when combined with other diagnostic and clinical findings.

The PAPP-A Rapid Test Device (Serum) uses a fluorescence immunoassay method. Fluorescence-based immunoassay technology is widely used in modern diagnostics because it supports sensitive detection of biomarkers from biological specimens.

Benefits

• Serum-based PAPP-A testing support
• Fluorescence immunoassay method
• Suitable for professional diagnostic laboratories
• Supports first-trimester pregnancy screening
• Useful for prenatal risk assessment workflows
• Designed for gynecology, maternity, and diagnostic settings
• Reliable option for international healthcare markets
• Supports efficient testing and reporting systems

The correct specimen for the PAPP-A Rapid Test Device is serum. Proper sample collection, serum separation, storage, and handling are important for reliable test performance.

Guidance

• Use serum specimens only as recommended
• Follow approved blood collection procedures
• Separate serum according to laboratory protocol
• Avoid hemolyzed, contaminated, or improperly stored specimens
• Use compatible fluorescence analyzer systems if required
• Allow reagents and samples to reach recommended testing conditions if instructed
• Follow the LARKSOIS Pharma product insert carefully

Note

The PAPP-A Rapid Test Device should be used only by trained healthcare or laboratory professionals in professional diagnostic environments.

Steps

• Bring the test device, serum sample, and reagents to the required testing temperature
• Open the sealed test package only when ready to perform the test
• Prepare the serum specimen according to the product insert
• Apply the required amount of serum or prepared sample to the test device
• Use the compatible fluorescence analyzer system where required
• Allow the test reaction to complete within the instructed time
• Read and report the result according to the approved interpretation guidance

Note

The exact testing procedure should follow the official LARKSOIS Pharma product insert and compatible fluorescence analyzer instructions.

Positive

Abnormal or low PAPP-A values may support further clinical review when interpreted with gestational age, ultrasound findings, free β-hCG, maternal age, and medical history.

Negative

A result within the expected reference range may support lower risk assessment when interpreted with other screening parameters, but it does not replace clinical monitoring or professional pregnancy care.

Invalid

If the analyzer, control system, or test device indicates an invalid result, repeat testing should be performed according to the product insert and laboratory quality-control procedure.

Instructions

• Store according to the temperature stated on the product label
• Keep the test device sealed until use
• Protect from direct sunlight and moisture
• Do not use expired test devices
• Do not use damaged or contaminated packaging
• Use compatible fluorescence analyzer systems if required
• Dispose of used diagnostic materials according to laboratory safety rules

Instructions

• For professional in vitro diagnostic use only
• Not intended for home-based testing
• Not a standalone diagnostic test for fetal abnormalities
• Results should be interpreted with gestational age, ultrasound findings, free β-hCG, maternal age, and clinical history
• Low PAPP-A requires medical review, not panic
• High, normal, or low values may vary depending on laboratory standards and gestational age
• Follow local regulatory and clinical screening guidelines

LARKSOIS Pharma focuses on diagnostic solutions that meet the needs of global healthcare providers, laboratories, hospitals, and distributors. The PAPP-A Rapid Test Device (Serum) is designed for professional prenatal screening workflows and pregnancy biomarker evaluation.

Advantages

• Serum-based PAPP-A testing support
• Fluorescence immunoassay method
• Suitable for professional diagnostic laboratories
• Supports first-trimester pregnancy screening
• Useful for prenatal risk assessment workflows
• Designed for gynecology, maternity, and diagnostic settings
• Reliable option for international healthcare markets
• Supports efficient testing and reporting systems